Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib, Nivolumab, and Ipilimumab in Advanced Chemotherapy Resistant Metastatic MSS Colorectal Cancer
NCT04362839Phase 1Completed
- Sponsor
- City of Hope
- Start
- May 2020
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of regorafenib in colorectal cancer (CRC), sponsored by City of Hope. Primary endpoint: Recommended dose level of the combination. Started May 2020; status: completed.
02
Drugs
regorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04362839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04362839.